PURPOSE: To enhance the clinician's competence in providing local wound care for malignant and palliative wounds.
TARGET AUDIENCE: This continuing education activity is intended for physicians and nurses with an interest in skin and wound care.
OBJECTIVES: After participating in this educational activity, the participant should be better able to:
1. Apply patient prognosis to realistic outcomes, patient education, and pain management strategies.
2. Demonstrate ability to assess wounds and select appropriate dressings.
3. Analyze patient scenarios for use of various non-dressing wound treatment modalities.
Kevin Y. Woo, PhD, MSc, RN, ACNP, GNC(C), FAPWCA • Wound Care Consultant • West Park Health Care Centre • Toronto, Ontario, Canada • Research Associate • Toronto Regional Wound Clinics • Toronto • Associate Director, Wound Prevention and Care, Masters of Science in Community Health • Dalla Lana School of Public Health • University of Toronto • Assistant Professor • Lawrence S. Bloomberg Faculty of Nursing • University of Toronto
R. Gary Sibbald, BSc, MD, MEd, FRCPC (Med Derm), MACP, FAAD, MAPWCA • Professor of Public Health Science and Medicine • University of Toronto • Toronto, Ontario, Canada • Director • International Interprofessional Wound Care Course & Masters of Science in Community Health • Dalla Lana School of Public Health • University of Toronto • President • World Union of Wound Healing Societies • Clinical Associate Editor • Advances in Skin & Wound Care • Ambler, Pennsylvania
Dr Woo has disclosed that he is/was a recipient of grant/research funding from Mölnlycke, 3M, KCI, BSN Medical, Systagenix, Medline, and Ogenix; he was a recipient of grant/research funding from the Canadian Association of Wound Care and the Registered Nurses Association of Ontario; he is/was a consultant/advisor to ConvaTec and Hollister; Healthpoint, and the Canadian Association of Wound Care; and is/was a member of the speaker's bureau for Coloplast and Mölnlycke. Dr Sibbald has disclosed that he is a recipient of grant/research funding from 3M, Smith & Nephew, and ConvaTec; is a consultant/advisor to Coloplast, Covidien, and Mölnlycke; and is a member of the speaker's bureau for KCI, Johnson & Johnson (Systagenix), the Government of Ontario, and the Registered Nurses Association of Ontario. The authors have disclosed they will discuss unlabeled/investigational uses for Biatain Ibu.
All staff and faculty, including spouses/partners (if any), in a position to control the content of this CME activity have disclosed that they have no financial relationships with, or financial interests in, any commercial companies pertaining to this educational activity.
This continuing educational activity will expire for physicians on September 30, 2011.